Get the Stockscreener App
59.69
1.83%
1.1813
Vaxcyte Inc stock is traded at $59.69, with a volume of 217.90K.
It is up +1.83% in the last 24 hours and up +12.99% over the past month.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
See More
Previous Close:
$58.51
Open:
$58.42
24h Volume:
217.90K
Relative Volume:
0.16
Market Cap:
$8.58B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-12.98
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
+10.13%
1M Performance:
+12.99%
6M Performance:
+84.52%
1Y Performance:
-25.28%
1-Day Range:
$58.16
$61.25
1-Week Range:
$52.86
$61.25
52-Week Range:
$27.66
$83.33
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
59.76 | 8.40B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.08 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.29 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
831.10 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.49 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Reiterated | Needham | Buy |
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Earnings Outlook For Vaxcyte - Benzinga
Aug Movers: Whats the RSI of Vaxcyte Inc stockRisk Management & Safe Entry Trade Signal Reports - baoquankhu1.vn
Volume Report: Is Vaxcyte Inc affected by consumer sentiment2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Retail: What hedge funds are buying MFS High Yield Municipal TrustDividend Hike & AI Powered Market Trend Analysis - baoquankhu1.vn
Technical Analysis: Is PSMT a defensive stockPrice Action & Daily Volume Surge Signals - baoquankhu1.vn
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors - TipRanks
Vaxcyte shows market leadership with jump to 85 RS rating - MSN
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials - Finviz
Vaxcyte (PCVX) $632.5M stock offering follows bullish Cantor Fitzgerald rating - MSN
Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating - Finviz
Vaxcyte (PCVX) price target increased by 19.72% to 99.96 - MSN
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX) - Bitget
Should Vaxcyte’s OPUS-3 Phase 3 VAX-31 Trial Milestone Require Action From Vaxcyte (PCVX) Investors? - Yahoo Finance
Precision Trading with Vaxcyte Inc. (PCVX) Risk Zones - Stock Traders Daily
Nasdaq Moves: What is the target price for Vaxcyte Inc. stockEarnings Overview Summary & Verified Short-Term Plans - mfd.ru
Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit - MarketBeat
Is now the right time to enter Vaxcyte Inc.Market Activity Report & Safe Capital Growth Tips - mfd.ru
Vaxcyte (PCVX) Initiates Phase 3 Trial for VAX-31 Vaccine in Adu - GuruFocus
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - The Manila Times
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial - GlobeNewswire
Vaxcyte, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 - Quiver Quantitative
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - marketscreener.com
Vaxcyte to Report Fourth Quarter and Full Year 2025 - GlobeNewswire
IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc. - MarketBeat
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline - Sahm
Aug Wrap: Does Stepan Company have consistent dividend growth2025 AllTime Highs & Fast Gain Swing Alerts - baoquankhu1.vn
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - 富途牛牛
Commit To Buy Vaxcyte At $45, Earn 19.3% Annualized Using Options - Nasdaq
Technical Reactions to PCVX Trends in Macro Strategies - Stock Traders Daily
Vaxcyte closes $632.5 million public offering of common stock By Investing.com - Investing.com India
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position - The Globe and Mail
Is It Time To Reassess Vaxcyte (PCVX) After Recent Share Price Recovery - Yahoo Finance
Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Momentum - Yahoo Finance
Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus - Yahoo Finance
Vaxcyte (NASDAQ:PCVX) Stock Price Up 8.1%Time to Buy? - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring A Potential 90.61% Upside For Investors - DirectorsTalk Interviews
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Investing News Network
Vaxcyte Closes Public Offering of Shares - marketscreener.com
Vaxcyte closes $632.5 million public offering of common stock - Investing.com
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Vaxcyte, Inc. Completes $632.5 Million Public Offering of Common Stock - Quiver Quantitative
Guggenheim Reiterates Buy Rating on Vaxcyte (PCVX) at $116 Targe - GuruFocus
Vaxcyte (NASDAQ:PCVX) Earns Buy Rating from Guggenheim - MarketBeat
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.09%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):